Hypertension is a leading risk factor for cardiovascular morbidity and mortality. Despite the
widespread availability of both pharmacological and lifestyle therapeutic options, blood …

BACKGROUND: Several sham-controlled trials have investigated the efficacy and safety of
catheter-based renal denervation (RDN) with mixed outcomes. We aimed to perform a …

Renal denervation as an option for difficult to treat hypertension has been a concept for
several decades, with recent US FDA approval of new, minimally invasive devices …

Renal denervation (RDN) is a minimally invasive, endovascular catheter-based procedure
using radiofrequency, ultrasound, or alcohol-mediated ablation to treat resistant …

Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared
to sham at 2 months in patients with resistant hypertension in the multicenter, blinded …

Renal artery denervation has re-emerged as a potential therapeutic option for patients with
hypertension, especially those resistant to conventional pharmacotherapy. This …

Abstract The US Food and Drug Administration has approved renal denervation (RDN) as a
new treatment option for hypertension (HT) because it not only has antihypertensive effects …

Abstract William Bayliss and Ernest Starling are not only famous as pioneers in
cardiovascular physiology, but also responsible for the discovery of the first hormone (from …

In 2023, there were several new developments in the field of cardionephrology with potential
impact on the care of patients with dual burden of heart and kidney disease. With new drugs …

The US Food and Drug Administration recently approved 2 renal denervation (RDN)
systems, the ultrasound-based RDN (uRDN, Recor Paradise) and the multipolar …